The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
NLRP3: A Novel Mediator in Cardiovascular Disease
Open accessAbstract
Cardiovascular disease is a major cause of death worldwide. Inflammasome infiltration has been identified to play a central role in the pathological progression of certain cardiovascular diseases, such as vascular damage spanning atherosclerosis, aneurysm, or arteritis; ischemic heart disease; and other nonischemic heart diseases including diabetic cardiomyopathy, chronic heart failure, and hypertension- or virus-induced cardiac dysfunction. The NLRP3 inflammasome, a key participant in the innate immune response, requires both priming and activation signals for the initiation of inflammation. Piling evidence has revealed that the NLRP3 inflammasome could exert an inflammatory effect by inducing the secretion of proinflammatory cytokines (i.e., IL-1 β, IL-18) or could cause pyroptosis, a novel programmed cell death process, in a caspase-1-dependent manner. The importance of the NLRP3 inflammasome in cardiac disease has been broadly investigated. In this review, we present the current knowledge regarding the function of NLRP in vascular disease, ischemic heart disease, and nonischemic heart disease and discuss the potential therapeutic options targeting the NLRP3 inflammasome.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals
Duewell, P., Kono, H., Rayner, K. J., Sirois, C. M., Vladimer, G., Bauernfeind, F. G., Abela, G. S., Franchi, L., Nuñez, G., Schnurr, M., et al. (2010) · Nature · doi:10.1038/nature08938 · Cited by 4,026
Cryopyrin activates the inflammasome in response to toxins and ATP
Mariathasan, S., Weiss, D. S., Newton, K., McBride, J., O'Rourke, K., Roose-Girma, M., Lee, W. P., Weinrauch, Y., Monack, D. M., & Dixit, V. M. (2006) · Nature · doi:10.1038/nature04515 · Cited by 3,080
Hornung, V., Bauernfeind, F., Halle, A., Samstad, E. O., Kono, H., Rock, K. L., Fitzgerald, K. A., & Latz, E. (2008) · Nature Immunology · doi:10.1038/ni.1631 · Cited by 3,065
Activation of the NALP3 inflammasome is triggered by low intracellular potassium concentration
Pétrilli, V, Papin, S., Dostert, C., Mayor, A., Martinon, F., & Tschopp, J. (2007) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4402195 · Cited by 1,445
Kawaguchi, M., Takahashi, M., Hata, T., Kashima, Y., Usui, F., Morimoto, H., Izawa, A., Takahashi, Y., Masumoto, J., Koyama, J., et al. (2011) · Circulation · doi:10.1161/circulationaha.110.982777 · Cited by 884
NLRP3 Inflammasome as a Molecular Marker in Diabetic Cardiomyopathy
Luo, B., Huang, F., Liu, Y., Liang, Y., Wei, Z., Ke, H., Zeng, Z., Huang, W., & He, Y. (2017) · Frontiers in Physiology · doi:10.3389/fphys.2017.00519 · Cited by 213
Cited by
Metabolic syndrome and cardiovascular diseases: Going beyond traditional risk factors
Silveira Rossi, J. L., Barbalho, S. M., Reverete de Araujo, R., Bechara, M. D., Sloan, K. P., & Sloan, L. A. (2022) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3502 · Cited by 604
Role of pyroptosis in cardiovascular diseases
Jia, C., Chen, H., Zhang, J., Zhou, K., Zhuge, Y., Niu, C., Qiu, J., Rong, X., Shi, Z., Xiao, J., et al. (2019) · International Immunopharmacology · doi:10.1016/j.intimp.2018.12.028 · Cited by 267
Therapeutic potential of MCC950, a specific inhibitor of NLRP3 inflammasome
Li, H., Guan, Y., Liang, B., Ding, P., Hou, X., Wei, W., & Ma, Y. (2022) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2022.175091 · Cited by 258
Exendin-4 Protects against Hyperglycemia-Induced Cardiomyocyte Pyroptosis via the AMPK-TXNIP Pathway
Wei, H., Bu, R., Yang, Q., Jia, J., Li, T., Wang, Q., & Chen, Y. (2019) · Journal of Diabetes Research · doi:10.1155/2019/8905917 · Cited by 91
Self-citation
Metadata
- Authors
- Zhou, W., Chen, C., Chen, Z., Liu, L., Jiang, J., Wu, Z., Zhao, M., & Chen, Y.
- Venue
- Journal of Immunology Research
- Publisher
- Wiley
- Published
- 2018
- Volume
- 2018
- Pages
- 1-8
- ISSN
- 2314-7156 (ISSN-L)
- 2314-8861
- OpenAlex
- W2796243384
- Cited by
- 172
- References
- 6
- FWCI
- 7.77
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: NLRP3: A Novel Mediator in Cardiovascular Disease. https://app.cochat.ai/papers/10.1155/2018/5702103
- The paper
- Zhou, W., Chen, C., Chen, Z., Liu, L., Jiang, J., Wu, Z., Zhao, M., & Chen, Y. (2018). NLRP3: A Novel Mediator in Cardiovascular Disease. Journal of Immunology Research. https://doi.org/10.1155/2018/5702103
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.